The BIOSECURE Act- US legislation aimed at safeguarding the country’s interests against potential security threats from China - is facing further delay.
Passed by the House of Representatives in September, further passage of the bill has been held up and the latest delay has seen the act excluded from a key defense bill.
The omission of the legislation from the National Defense Authorization Act means that there is only one further opportunity to pass it before the conclusion of the congressional session.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze